Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Rated “Moderate Buy” by Wall Street Brokerages

Avalyn Pharma Inc. (NASDAQ:AVLN) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $60.00.

A number of brokerages have issued reports on AVLN. Raymond James Financial began coverage on shares of Avalyn Pharma in a research report on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price objective for the company. Weiss Ratings started coverage on shares of Avalyn Pharma in a research report on Thursday, August 13th. They set a “sell (d+)” rating on the stock. Morgan Stanley boosted their target price on Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Finally, Wall Street Zen downgraded Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th.

Institutional Trading of Avalyn Pharma

A number of hedge funds have recently bought and sold shares of AVLN. Manchester Capital Management LLC purchased a new stake in Avalyn Pharma during the third quarter worth about $36,000. Bank of New York Mellon Corp bought a new stake in Avalyn Pharma in the second quarter worth about $1,321,000. State Street Corp purchased a new position in Avalyn Pharma in the second quarter valued at about $10,501,000. Braidwell LP purchased a new position in Avalyn Pharma in the second quarter valued at about $26,382,000. Finally, Montanova Capital LLC bought a new position in shares of Avalyn Pharma during the 2nd quarter valued at approximately $82,402,000.

Avalyn Pharma Price Performance

Shares of AVLN stock opened at $26.04 on Monday. The firm has a 50-day moving average price of $31.37. The stock has a market capitalization of $1.15 billion and a P/E ratio of -1.14. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. Avalyn Pharma has a one year low of $22.24 and a one year high of $40.17.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.05. As a group, research analysts expect that Avalyn Pharma will post -3.86 earnings per share for the current fiscal year.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company’s research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.